香港股市 將在 5 小時 47 分鐘 開市
探索/

最活躍細價股

最活躍細價股

62.88k 個跟隨者31 個股票代號 追蹤清單由 Yahoo Finance 提供

跟隨此清單即可探索和追蹤每日成交量最高的細價股。

策劃人: Yahoo Finance

跟隨此清單即可探索和追蹤每日成交量最高的細價股。

此清單包括每日股價變化超過 3%,而且股價為 $5 美元或以下的股票。此清單每天產生一次,並以市值排序;盈利以最新收市價計算得出,而且只列出符合條件的前 30 名股票。

背景

Yahoo 財經運用先進的演算法觀察和偵測全球金融市場的趨勢。我們會以觀察名單的形式向你提供深入分析。

你可以透過 Yahoo 財經篩選器尋找其他有用的投資意見。

這些股票如何加權?

此觀察名單的股票比重相等。

表現

追蹤清單今日股價變化1 個月回報1 年回報總回報
最活躍細價股+20.33%---
^GSPC+1.03%+5.18%+32.73%+6087.73%

31 個股票代號

代號公司名稱收市價變化% 變化市場時間成交量平均成交量 (3 個月)市值
GERNGeron Corporation4.285+0.13+3.25%下午3:43 [EDT]4.24M9.03M2.58B
ACCDAccolade, Inc.4.11+0.14+3.53%下午3:43 [EDT]7.35M1.16M328.83M
GGRGogoro Inc.0.6767+0.02+2.70%下午3:42 [EDT]4.25M1.12M199.67M
WWWW International, Inc.1.155+0.37+46.57%下午3:43 [EDT]32.66M2.69M92.09M
SKKSKK Holdings Limited5.3261+1.33+33.20%下午3:43 [EDT]6.25M24.88k83.22M
PDYNPalladyne AI Corp.2.6+0.72+38.30%下午3:43 [EDT]20.63M100.07k69.68M
CYBLCyberlux Corporation0.0106+0.00+12.77%下午3:27 [EDT]43.59M3.89M63.02M
SVMHSRIVARU Holding Limited0.0752+0.00+1.21%下午3:42 [EDT]10.92M6.06M32.80M
GRTSGritstone bio, Inc.0.1999+0.01+7.47%下午3:43 [EDT]6.66M1.98M24.12M
TNXPTonix Pharmaceuticals Holding Corp.0.1405-0.00-2.36%下午3:43 [EDT]43.83M25.72M19.67M
ICBUiMD Companies, Inc.0.0044+0.00+12.82%下午3:22 [EDT]10.08M15.41M18.07M
NSAVNet Savings Link, Inc.0.0025+0.00+19.05%下午3:23 [EDT]6.42M24.22M17.80M
LUXHLuxUrban Hotels Inc.0.0743+0.00+2.92%下午3:43 [EDT]17.14M6.14M10.83M
CDTConduit Pharmaceuticals Inc.0.1082+0.01+8.20%下午3:43 [EDT]7.81M14.06M10.39M
AKTSAkoustis Technologies, Inc.0.0848+0.01+13.22%下午3:43 [EDT]11.99M9.77M9.66M
OTRKOntrak, Inc.2.84+1.02+56.04%下午3:43 [EDT]97.38M68.49k9.08M
VERBVerb Technology Company, Inc.0.0445+0.00+5.95%下午3:43 [EDT]135.61M13.87M7.54M
HIRUHiru Corporation0.0032+0.00+6.67%下午3:24 [EDT]13.45M72.72M6.21M
AGRIAgriFORCE Growing Systems Ltd.0.0609+0.01+26.87%下午3:43 [EDT]335.40M17.69M5.98M
NMHINature's Miracle Holding Inc.0.176+0.04+29.60%下午3:43 [EDT]106.57M1.03M5.93M
VIRIVirios Therapeutics, Inc.0.1579+0.02+14.50%下午3:43 [EDT]41.01M985.04k5.34M
BURUNuburu, Inc.0.9917+0.54+121.81%下午3:43 [EDT]109.91M2.03M4.41M
IGEXIndo Global Exchange(s) PTE, Ltd.0.0005+0.00+25.00%下午3:48 [EDT]7.53M8.50M3.06M
BPTHBio-Path Holdings, Inc.1.16+0.29+33.67%下午3:43 [EDT]64.16M329.63k2.96M
IVPInspire Veterinary Partners, Inc.0.2829+0.01+4.81%下午3:42 [EDT]4.02M4.54M2.08M
PBMPsyence Biomedical Ltd.0.1098+0.00+3.58%下午3:42 [EDT]9.62M4.55M1.83M
VIZCVizConnect, Inc.0.0003--下午2:39 [EDT]220.00k4.29M1.43M
GRIGRI Bio, Inc.0.4051+0.07+19.46%下午3:43 [EDT]8.79M776.68k1.23M
GSTCGlobeStar Therapeutics Corporation0.0004+0.00+33.33%下午4:00 [EDT]32.27M7.72M496.44k
KITLKisses From Italy Inc.0.0012+0.00+33.33%下午2:56 [EDT]6.06M1.39M447.50k
  • Investopedia

    WeightWatchers Stock Soars on Copycat Weight-Loss Drug Offering

    Shares of WW International, better known as WeightWatchers, soared Tuesday after it said it is offering copycat weight-loss drugs to its members.

  • Yahoo Finance Video

    WeightWatchers stock pops on compounded GLP-1 weight-loss medication

    Shares of WeightWatchers (WW) are climbing after the company announced a compounded GLP-1 medication starting at $129 as it seeks to make the weight-management solution "accessible and affordable." Catalysts Hosts Seana Smith and Madison Mills report more on the story and how it can compete with GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Ozempic and Eli Lilly's (LLY) Mounjaro. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl

  • Benzinga

    Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer

    Bio-Path Holdings, Inc., (NASDAQ:BPTH) stock is trading higher on Tuesday with a strong session volume of 25.89 million compared to an average of 328.97K as per data from Benzinga Pro. The company initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases. This program marks the first application of DNAbilize technology to develop a non-cancer application. The company expects to begin preclinical studies to confirm these assumptions in the fourth quar